NOVATO, CA (Thursday, November 18, 2010) – Biosearch Technologies, Inc. (Biosearch), a leading supplier of sophisticated oligonucleotide components to the rapidly growing molecular diagnostics industry, today announced that the company has licensed access to the new “pdm” H1N1 signatures from Centers for Disease Control and Prevention (CDC). The new “pdm” panel is optimized to achieve enhanced sensitivity and specificity for H1N1 specimen.
Responding to the outbreak of the Novel 2009 H1N1 and concurrently circulating “Seasonal” Influenza A (A/H1N1, H3N2) and B viruses in April of 2009, CDC designed and validated molecular diagnostic probes and primers (“signatures”) used in real-time RT-PCR detection assays. Subsequent molecular and antigenic evolution associated with the geographical spread of Novel 2009 H1N1 influenza viruses has prompted CDC to design and validate new “pdm” molecular signatures. These new “pdm” signatures qualitatively detect currently circulating Novel 2009 H1N1 and demonstrate improved performance over the probe and primer sequences previously published on the World Health Organization’s (WHO) website.
“Today’s announcement advances Biosearch Technologies’ ardent support for CDC in emerging and actionable respiratory assays. Biosearch is dedicated in the pursuit of improved public health surveillance and disease prevention,” comments Marc Beal, Director of Corporate Development at Biosearch Technologies. “As licensors of CDC influenza signatures and as the inventors of BHQ® (Black Hole Quencher®) technology, Biosearch will provide access to 5’-Nuclease BHQ probes that meet CDC design and manufacturing specifications for PDM Novel 2009 H1N1 testing labs around the world.”
Biosearch was the first to license Influenza signatures from CDC, which conferred rights to Biosearch under the CDC patents to manufacture and sell dual-labeled probes and primers bearing the Novel 2009 H1N1 and Influenza A sub-typing signatures. For product details, please visit www.biosearchtech.com/valupanel for more details.
About Biosearch Technologies, Inc.
Biosearch Technologies, Inc. is a privately held, ISO 9001:2008 certified company, located in northern California. Founded in 1993, Biosearch is a leader in the design, development and manufacture of sophisticated oligonucleotide-based tools. Products include fluorophores (CAL Fluor®, Quasar® and Pulsar® dyes) and dark quenchers (Black Hole Quencher® dyes) to be included in custom-synthesized probe formats for real-time, quantitative PCR and other genomic-based applications.
In addition to basic R&D applications, Biosearch now leverages its demonstrated expertise in fully assembled RUO kits and the cGMP manufacture of oligonucleotide components for molecular diagnostic assays. Biosearch Technologies is registered with the FDA (registration number 300300905), and as such, its contract manufacturing processes conform to all applicable GMP requirements per 21 CFR Part 820. Biosearch markets include pharmaceutical, in-vitro diagnostic, biotech, ag/bio, environmental and food testing, public health, and biodefense sectors.
For additional information about Biosearch Technologies, Inc., contact email@example.com or visit www.biosearchtech.com.